IMMUCELL CORP /DE/
No enriched coverage for $ICCC in the last 7 days.
No SEC Form 4 filings for $ICCC in the last 30 days.
See all $ICCC insider activity →ImmuCell (ICCC) reported Q2 2026 earnings with product sales of $7.2M, up 11.5% YoY, and net income per diluted share of $0.20. Gross margin decreased to 33.9% from 43.7% YoY due to manufacturing costs. The company is investing in capacity expansion and focusing on its First Defense product line, with U.S. sales growing 27.7% YoY and market share increasing to 19%. Cash and cash equivalents were $8.9M as of June 30, 2026.
ImmuCell (NASDAQ:ICCC) reported Q2 gross margin of 33.9% of product sales, down from 43.7% a year earlier and 11.1 points below Q1 2026, citing lower output, about $150,000 in scrap, and Re-Tain cost shifts. U.S. sales rose 32.5% in H1 2026; distributor volumes grew 24% YoY. The company plans $3.5M freeze-drying and $4.5M liquids capacity expansions through 2027.
IMMUCELL CORP /DE/ (ICCC) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ImmuCell ImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2026 For Immediate Release PORTLAND, Maine – August 13, 2026 – ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health biologics company that develops,
Recent ICCC coverage spans earnings, financial news and market movers.
Earnings beat on top line but margin compression; settlement boost to net income.
Margin compression and production seasonality are the near-term drivers, partially offset by planned capacity expansion through 2027.
Q2 shows improving top-line and profitability, but gross margin fell sharply versus last year due to manufacturing headwinds and expense shifts.
The stock move is tied to a specific sales print and a named product driver (Tri-Shield First Defense).
Preliminary sales growth, especially domestic, is a near-term positive read-through for ICCC ahead of the Aug 14 full results call.
alphai scores every news story that mentions ICCC with an AI model for sentiment and relevance, and aggregates insider trades from IMMUCELL CORP /DE/'s SEC EDGAR Form 4 filings. Figures refresh continuously.
ImmuCell (ICCC) reported Q2 2026 earnings with product sales of $7.2M, up 11.5% YoY, and net income per diluted share of $0.20. Gross margin decreased to 33.9% from 43.7% YoY due to manufacturing costs. The company is investing in capacity expansion and focusing on its First Defense product line, with U.S. sales growing 27.7% YoY and market share increasing to 19%. Cash and cash equivalents were $8.9M as of June 30, 2026.
2 min readImmuCell (NASDAQ:ICCC) reported Q2 gross margin of 33.9% of product sales, down from 43.7% a year earlier and 11.1 points below Q1 2026, citing lower output, about $150,000 in scrap, and Re-Tain cost shifts. U.S. sales rose 32.5% in H1 2026; distributor volumes grew 24% YoY. The company plans $3.5M freeze-drying and $4.5M liquids capacity expansions through 2027.
4 min readIMMUCELL CORP /DE/ (ICCC) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ImmuCell ImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2026 For Immediate Release PORTLAND, Maine – August 13, 2026 – ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health biologics company that develops,
6 min readBiotech stocks hit 52-week highs on July 10, 2026. American Well (AMWL) reached $10.16, citing Nature coverage of SilverCloud and insurer-related deals, and guided 2026 revenue to $195M-$205M. Cue Biopharma (CUE) hit $45.50 amid a ~$50M private placement. ImmuCell (ICCC) rose to $11.59 after Q2 sales of $7.2M. Scholar Rock (SRRK) hit $58.49 on BLA acceptance for apitegromab, with FDA response due by Sept. 30. Faeth (FTH) touched $36.89 on PIKTOR trial timelines.
5 min readImmuCell (Nasdaq: ICCC) reported preliminary, unaudited sales for Q2 2026. Total product sales were $7.2 million, up 11.5% year over year, with domestic sales up 27.7% and international down 38.9%. For the first six months, sales rose 20.9% to $17.5 million. Management will discuss results on Aug. 14, 2026.
3 min readIMMUCELL CORP /DE/ (ICCC) filed an SEC Form 8-K — Results of Operations and Financial Condition. iccc20260708_8k.htm false 0000811641 0000811641 2026-07-09 2026-07-09 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event repo
2 min readte Boekhorst Paul Francis Olivier (President and CEO) purchased 8,000 shares of IMMUCELL CORP /DE/ (ICCC) at $9.50 on 2026-06-18.
1 min readIMMUCELL CORP /DE/ (ICCC) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. iccc20260615_8k.htm false 0000811641 0000811641 2026-06-11 2026-06-11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event repo
2 min readImmuCell Corporation (NASDAQ:ICCC) has announced new employment agreements and stock option grants for CFO Timothy C. Fiori and SVP of Sales and Marketing Bobbi Jo Brockmann, effective January 27. The agreements include base salaries, performance-based annual cash bonuses, and stock options vesting over three years. Additionally, CEO Olivier te Boekhorst received a performance-based stock option grant contingent on significant net operating income growth for fiscal year 2025.
2 min readSAP's cloud and AI push, Novartis' strong drug lineup, and Philip Morris' smoke-free growth headline Zacks' latest analyst picks.
4 min read
